1.
Giles WL.
Boland,
et al.
Incidental adrenal lesions: principles,
techniques and algorithms for imaging characterization.
Radiology 2008; 249: 756-775.
2.
Khaled M.
Elsayes,
et al.
Adrenal masses: MR imaging features with pathologic correlation.
Radiographics 2004; 24: 73-86.
3.
William W.
Mayo-Smith,
et al.
From the RSNA refresher courses: state-of-the-art adrenal imaging.
Radiographics 2001; 21: 995-1012.
4.
Minal J.
Sangwaiya,
et al.
Incidental adrenal lesions: accuracy of characterization with contrast-enhanced wash out multidetector CT-10 minute delayed imaging protocol revisited in a large patient cohort.
Radiology 2010; 256: 504-510.
5.
Peter F.
Hahn,
et al.
Adrenal lesions: attenuation measurement differences between CT scanners.
Radiology 2006; 240: 458-463.
6.
Daniele Marin,
et al.
Characterization of adrenal lesions: comparison of 2D and 3D dual gradient-echo MR imaging at 3T-preliminary results.
Radiology 2010; 254: 179-187.
7.
Young WF Jr.
The incidentally discovered adrenal mass.
N Engl J Med 2007; 356: 601-610.
8.
Dunnick NR,
Korobkin M.
Imaging of adrenal incidentalmomas.
AJR Am J Roentgenol 2002; 179: 559–568.
9.
Song JH,
Chaudhry FS,
Mayo-Smith WW.
The incidental indeterminate adrenal mass on CT: prevalence of adrenal disease in 1.049 consecutive adrenal masses in patients with no known malignancy.
AJR Am J Roentgenol 2008; 190: 1163-1168.
10.
Slattery JM,
Blake MA,
Kalra MK,
et al.
Adrenocortical carcinoma: contrast washout characteristics on CT.
AJR Am J Roentgenol 2006; 187: 21-24.
11.
Szolar DH,
Melvyn Korobkin M,
Reittner P,
et al.
Adrenocortical carcinomas and adrenal pheochromocytomas: mass and enhancement loss evaluation at delayed contrast-enhanced CT.
Radiology 2005; 234: 479–485.
12.
Benitah N,
Yeh BM,
Qayyum A.
Minor morphologic abnormalities of adrenal glands at CT: prognostic importance in patients with lung cancer.
Radiology 2005; 235: 517–522.
13.
Jhaveri KS,
Wong F,
Ghai S,
Haider MA.
Comparison of CT histogram analysis and chemical shift MRI in the characterization of indeterminate adrenal nodules.
AJR Am J Roentgenol 2006; 187: 1303-1308.
14.
Haider MA,
Ghai S,
Jhaveri K,
Lockwood G.
Chemical shift MR imaging of hyperattenuating (>10 HU) adrenal masses: does it still have a role?.
Radiology 2004; 231: 711-716.
15.
Park BK,
Kim CK,
Kim B,
Lee JH.
Comparison of delayed enhanced CT and chemical shift MR for evaluating hyperattenuating incidental adrenal masses.
Radiology 2007; 243: 760–765.
16.
Blake MA,
Kalra MK,
Maher MM,
et al.
Pheochromocytoma: an imaging chameleon.
Radiographics 2004; 24: 87-89.
17.
Bessell-Browne R,
O’Malley ME.
CT of pheochromocytoma and paraganglioma: risk of adverse events with IV administration of nonionic contrast material.
AJR Am J Roentgenol 2007; 188: 970–997.
18.
Siegel MJ,
Ishwaran H,
Fletcher BD,
et al.
Staging of neuroblastoma at imaging: report of the Radiology Diagnostic Oncology Group.
Radiology 2002; 223: 168-175.
19.
Kamiyama T,
et al .
Distinguishing adrenal adenomas from nonadenomas: combined use of diagnostic parameters of unenhanced and short 5-minute dynamic enhanced CT protocol.
Radiology 2009; 250: 474-481.
20.
Frilling A ,
Tecklenborg K ,
Weber F ,
et al.
Importance of adrenal incidentaloma in patients with a history of malignancy.
Surgery 2004; 136: 1289-1296.
21.
Schindera ST,
et al.
Effect of echo time pair selection on quantitative analysis for adrenal tumor characterization with in-phase and opposed-phase MR imaging: initial experience.
Radiology 2008; 248: 140-147.